Pharmacokinetics of flutoprazepam, a novel benzodiazepine drug, in normal subjects
- 16 Downloads
The single dose pharmacokinetics of flutoprazepam and its active N-desalkyl metabolite were determined in 8 normal subjects by using newly developed, highly sensitive, GC-MS and HPLC techniques. Following a 2 mg dose of the drug, the concentrations of unchanged flutoprazepam in serum were extremely low (below 5 ng/ml at 2 h) and declined rapidly to undetectable levels within 6–9 h after dosing. At all sampling times, the serum concentration of the N-dealkylated metabolite (N-desalkylflurazepam) was much greater than that of the parent compound. This metabolite appeared in serum rapidly (within 2 h), reached a peak between 2 and 12 h and declined slowly, with an elimination half-life of about 90 h on average. The serum concentration of two additional putative metabolites (3-hydroxy-flutoprazepam and N-desalkyl-3-hydroxy-flutoprazepam) was below the limit of detection (2 ng/ml) in all samples. Mild CNS effects (documented by prolonged choice reaction time) were present at 2 and 4 h but were no longer detectable at 9 h. It is suggested that unchanged flutoprazepam is unlikely to contribute significantly to clinical effects and that the drug exerts its therapeutic activity through conversion to the slowly eliminated N-desalkyl metabolite.
KeywordsFlutoprazepam pharmacokinetics benzodiazepine humans
Unable to display preview. Download preview PDF.
- 2.Kanebo Pharmaceuticals Ltd., unpublished data.Google Scholar
- 3.Tsutsui S., Nisbida K., Namba T., Saito T. (1982): Clinical study of KB 509 (flutoprazepam) on psychosomatic disorders and neuroses (double-blind test). Jpn. Pharmacol. Ther., 10, 6337–6351.Google Scholar
- 4.Kudo Y.,TanakaS. (1980): Clinical pharmacology of KB 509. In: Turner P., Padgham C. (eds), Abstracts World Conference on Clinical Pharmacology and Therapeutics, London, Abstract 0242.Google Scholar
- 5.Midorikawa T., Miura S., Sato M., Sakurai S., Awata N. (1982): The metabolic fate of 7-cbloro-l-cyclopropyl-methyll, 3-dihydro-5-(2-fluorophenyl)-2H-1,4-benzodiazepin-2-one (KB 509). I. Metabolism in dogs, mice and rats. Iyakukin. Kenkyu, 13, 309.Google Scholar
- 6.Sakurai S., Miura S., Sato M., Midorikawa T., Awata N. (1982): The metabolic fete of 7-chloro-l-cyclopropyl-methyl-1,3-dfliydro-5-(2-fluorophenyl)-2H-1,4-enzodiazepin-2-one (KB 509). II. Absorption, distribution and excretion in rats, mice and dogs. Iyakukin. Kenkyu, 13, 309.Google Scholar
- 7.Kageyama T. Phase I study of flutoprazepam (KB 509). Single dose study 1987. Kanebo Pharmaceuticals Ltd., Unpublished dataGoogle Scholar